Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05790655 · ClinicalTrials.gov registry record · NA
Ovarian PRP for Diminished Ovarian Reserve
A NA study of Diminished Ovarian Reserve, sponsored by Generation Next Fertility.
- Recruiting
- Registry status
- NA
- Development phase
- 230
- Enrollment target
- 1
- Study location
NCT05790655: Recruiting NA study of Diminished Ovarian Reserve, sponsored by Generation Next Fertility.
NCT05790655 is a NA study of Diminished Ovarian Reserve that is actively recruiting participants, run by Generation Next Fertility. The registered enrollment target is 230 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05790655, a NA study of Diminished Ovarian Reserve, is actively recruiting participants, sponsored by Generation Next Fertility.
- RECRUITING
- Registry status
- NA
- Development phase
- 230 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of pregnancy and live birth compared to age-matched peers with a normal or robust ovarian reserve.
Primary Outcome
Total oocyte yield
Conditions Studied
Interventions
- OTHER oPRP
- OTHER Placebo- Serum
Study Locations (1)
New York
- Generation Next Fertility - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-10-07 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What NCT05790655 shows while recruiting
NCT05790655 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Diminished Ovarian Reserve appearing as the primary indexed condition, and to 2 interventions - of which oPRP is the first listed.
NCT05790655 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05790655 about?
NCT05790655 is a clinical study titled "Ovarian PRP for Diminished Ovarian Reserve". This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of p...
What is the current status of trial NCT05790655?
This trial is currently recruiting. It is a NA study. The enrollment target is 230 participants. The study started on 2023-10-07. Estimated completion is 2025-12-31.
What conditions does trial NCT05790655 study?
This clinical trial studies the following conditions: Diminished Ovarian Reserve.
What interventions are being tested in trial NCT05790655?
The interventions under investigation include: oPRP (OTHER), Placebo- Serum (OTHER).
Who is sponsoring clinical trial NCT05790655?
This trial is sponsored by Generation Next Fertility, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05790655 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diminished Ovarian Reserve
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05790655's enrollment target sits among peer trials
230 465th of 2000 higher than 1,533 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI